Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REKHA JOHN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1619979846
CMS profile
118220
Location
KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$77.93

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $77.93 6

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REKHA JOHN

NPI 1619979846 · CMS profile ID 118220

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

KINSTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). REKHA JOHN, NPI 1619979846, CMS profile ID 118220. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
REKHA JOHN, NPI 1619979846, CMS profile ID 118220, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1619979846?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $77.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Relypsa, Inc. $12.2109/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683899319 CMS
AstraZeneca Pharmaceuticals LP $13.7404/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685168593 CMS
Otsuka America Pharmaceutical, Inc. $18.1404/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687410079 CMS
Relypsa, Inc. $11.2002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683898025 CMS
Otsuka America Pharmaceutical, Inc. $14.0301/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687410077 CMS
AKEBIA THERAPEUTICS INC $8.6101/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706564589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $77.93 6
PY2020 $119.67 2
PY2022 $404.00 18
PY2023 $539.51 20
PY2024 $2,789.07 18
PY2025 $388.84 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $499,069.81 26
PY2024 Principal investigator $549,482.70 50
PY2023 Principal investigator $376,752.37 57
PY2022 Recipient $7,645.61 7
PY2022 Principal investigator $353,881.30 372
PY2021 Principal investigator $168,644.86 191
PY2020 Principal investigator $154,822.49 45
PY2019 Principal investigator $231,281.89 292

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,000.00 12/15/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136589
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,952.00 12/06/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136639
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $6,554.00 12/06/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000138317
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $51.14 11/29/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000138337
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,409.00 11/16/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137463
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,305.00 10/12/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136599
Principal investigator 1 AstraZeneca Pharmaceuticals LP $173,219.60 09/27/2023 Non-covered Recipient Entity
MANUEL MONTERO
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions No dispute reported 06/30/2026 991134065
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,863.00 08/31/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000138327
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,125.00 08/28/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136659
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $52.15 08/28/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000138307
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,600.00 08/24/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000138283
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,002.00 08/10/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137443
Principal investigator 1 AKEBIA THERAPEUTICS INC $67.50 07/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909919
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 07/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909945
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,063.00 07/13/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136649
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,000.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909780
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,500.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909803
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,215.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909875
Principal investigator 1 AKEBIA THERAPEUTICS INC $540.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909897
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910793
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910817
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910837
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910861
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910885
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910907
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910931
Principal investigator 1 AKEBIA THERAPEUTICS INC $27.00 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910953
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910975
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910997
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999911023
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999911045
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999911071
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999911095
Principal investigator 1 AKEBIA THERAPEUTICS INC $26.75 06/20/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999911117
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,587.00 06/12/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137453
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,739.00 06/12/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137475
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,500.00 05/25/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137503
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $59.29 05/22/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137515
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,325.00 05/18/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137493
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $280.00 05/02/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136619
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $99.61 05/02/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136629
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $111.91 04/13/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000136609
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,100.00 04/13/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000138295
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $35.00 04/06/2023 Non-covered Recipient Entity
Interspond LLC
Efficacy and Safety of Finerenone in Combination with SGLT2i No dispute reported 06/30/2026 1000137485
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,250.00 03/24/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909735
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,713.52 03/24/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909849
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,250.33 03/17/2023 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 991124515
Principal investigator 1 AKEBIA THERAPEUTICS INC $756.00 02/27/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909715
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,000.00 02/27/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909757
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $42,464.37 01/26/2023 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES KINSTON OFFICE
A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease No dispute reported 06/30/2026 1006160722
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,600.00 01/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909827
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 01/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909971
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 01/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999909991
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,066.50 01/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910015
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,795.50 01/19/2023 Non-covered Recipient Entity
Eastern Nephrology Associates, PLLC
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 999910771
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $15,448.58 01/17/2023 Non-covered Recipient Entity
EASTERN NEPHROLOGY ASSOCIATES KINSTON OFFICE
A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin No dispute reported 06/30/2026 1006168479
Principal investigator 1 AstraZeneca Pharmaceuticals LP $65,287.12 01/02/2023 Non-covered Recipient Entity
MANUEL MONTERO
A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease No dispute reported 06/30/2026 991137887